组蛋白去乙酰化酶(HDACs)的研究进展论文(5)
2013-09-26 01:03
导读：[1] 谢爱华,廖晨钟,李伯玉.以组蛋白去乙酰化酶为靶标的抗癌药物研发进展[J]. 中国 新药杂志,2005,14(1):10-14. [2] NELSON S M，FERGUSON L R，DENNY W A.DNA and the chromo
[1] 谢爱华,廖晨钟,李伯玉.以组蛋白去乙酰化酶为靶标的抗癌药物研发进展[J].
中国新药杂志,2005,14(1):10-14.
[2] NELSON S M，FERGUSON L R，DENNY W A.DNA and the chromosome-varied targets for chemotherapy[J].Cell Chromosome,2004,3(1):2.
[3] GOLDBERG A D,ALLIS C D,BERNSTEIN E.Epigenetics:a landscape takes shape[J].Cell,2007,128(4):635-638.
[4] MINUCCI S,PELICCI P G.Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer[J].Nat Rev Cancer，2006,6(1):38-51.
[5] 陈忠南,徐克前.表观遗传学药物FK228的药理作用及机制[J].国际病理
科学与临床杂志,2008,28(4):297-301.
[6] 王生余,张旭辉.新型抗肿瘤药物组蛋白去乙酰化酶抑制剂[J].国际肿瘤杂志,2006,33(6):404-406.
[7] GREGORETTI I V,LEE Y M,GOODSON H V.Molecular evolution of the histone deacetylase family:functional implications of phylogenetic analysis[J].J Mol Biol,2004,338(1):17-31.
[8] BLANDER G,GUARENTE L.The Sir2 family of protein deacetylases[J].Annu Rev Biochem，2004,73(5):417-435.
[9] PFLUM M K，TONG J K，LANE W S，et al.Histone deacetylase 1 phosphorylation promotes enzymatic activity and complex formation[J].J Biol Chem,2001,276(50):47733-47741.
[10] BOTTOMLEY M J，LO SURDO P，DI GIOVINE P，et al. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural Zinc-binding domain[J].J Biol Chem,2008，283(39):26694-26704.
[11] TONG J J，LIU Jian-hong，BERTOS N R，et al. Identifi-cation of HDAC10,a novel class II human histone deacetylase containing a leucine-rich domain[J].Nuc Aci Res,2002,30(5):1114-1123.
